Grant C Hughes, MD | |
220 Unity St, Bellingham, WA 98225-4429 | |
(360) 676-6177 | |
Not Available |
Full Name | Grant C Hughes |
---|---|
Gender | Male |
Speciality | Rheumatology |
Experience | 23 Years |
Location | 220 Unity St, Bellingham, Washington |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912128257 | NPI | - | NPPES |
8433799 | Medicaid | WA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RR0500X | Internal Medicine - Rheumatology | MD00043465 (Washington) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Harborview Medical Center | Seattle, WA | Hospital |
University Of Washington Medical Ctr | Seattle, WA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
The Association Of University Physicians | 0446162697 | 3009 |
News Archive
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.
According to new research that looked at the TV viewing habits and sleep histories of 423 persons between ages of 18 and 25 years, binge watching or consuming multiple episodes of a TV series at one sitting can significantly affect sleep. Regular TV watching on the other hand does not affect sleep detrimentally to that extent according to study author Liese Exelmans a doctoral researcher at the University of Leuven's School of Mass Communication Research in Belgium. The study was published in the current issue of the Journal of Clinical Sleep Medicine.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key data supporting its lead brown fat biology program in the journal Nature.
KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
Blue Shield of California joins two other insurers who contend that other cancer treatments are just as good, and far less expensive.
› Verified 2 days ago
Entity Name | The Association Of University Physicians |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023041159 PECOS PAC ID: 0446162697 Enrollment ID: O20031105000244 |
News Archive
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.
According to new research that looked at the TV viewing habits and sleep histories of 423 persons between ages of 18 and 25 years, binge watching or consuming multiple episodes of a TV series at one sitting can significantly affect sleep. Regular TV watching on the other hand does not affect sleep detrimentally to that extent according to study author Liese Exelmans a doctoral researcher at the University of Leuven's School of Mass Communication Research in Belgium. The study was published in the current issue of the Journal of Clinical Sleep Medicine.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key data supporting its lead brown fat biology program in the journal Nature.
KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
Blue Shield of California joins two other insurers who contend that other cancer treatments are just as good, and far less expensive.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Grant C Hughes, MD 220 Unity St, Bellingham, WA 98225-4429 Ph: (360) 676-6177 | Grant C Hughes, MD 220 Unity St, Bellingham, WA 98225-4429 Ph: (360) 676-6177 |
News Archive
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the upcoming presentation of preclinical data from the company's lead program, VB-201, at the European League Against Rheumatism Annual European Congress of Rheumatology.
According to new research that looked at the TV viewing habits and sleep histories of 423 persons between ages of 18 and 25 years, binge watching or consuming multiple episodes of a TV series at one sitting can significantly affect sleep. Regular TV watching on the other hand does not affect sleep detrimentally to that extent according to study author Liese Exelmans a doctoral researcher at the University of Leuven's School of Mass Communication Research in Belgium. The study was published in the current issue of the Journal of Clinical Sleep Medicine.
Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key data supporting its lead brown fat biology program in the journal Nature.
KalVista Pharmaceuticals, a research-led pharmaceutical company, today announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE).
Blue Shield of California joins two other insurers who contend that other cancer treatments are just as good, and far less expensive.
› Verified 2 days ago
Katherine Morgan, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 2592 Kwina Rd, Bellingham, WA 98226 Phone: 360-384-0464 | |
Hannah Sheinin, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 2979 Squalicum Pkwy, Suite 301, Bellingham, WA 98225 Phone: 360-734-1420 Fax: 360-756-6666 | |
Ankur Mogla, MD Rheumatology Medicare: Medicare Enrolled Practice Location: 410 Birchwood Ave Ste 200, Bellingham, WA 98225 Phone: 360-734-9233 | |
Dr. Sumner Todd Mcallister, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 722 N State St, Bellingham, WA 98225 Phone: 360-752-2865 | |
Amir Gharaei, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3015 Squalicum Pkwy, Suite 140, Bellingham, WA 98225 Phone: 360-788-6112 | |
Scott Michael Letellier, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 3301 Squalicum Pkwy, Bellingham, WA 98225 Phone: 360-788-8222 Fax: 360-788-7759 | |
Dr. Sukhjit Singh Shergill, Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4545 Cordata Pkwy, Suite 2b, Bellingham, WA 98226 Phone: 360-738-2200 Fax: 360-752-5683 |